NDATOPICALEMULSION
Approved
Sep 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEXA-GERM (hexachlorophene) is a topical antimicrobial emulsion approved in 1974 for treating staphylococcal infections. The product functions as a broad-spectrum antiseptic agent applied directly to affected skin areas. It represents an older-generation topical antibiotic with established clinical utility in dermatological care.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity), indicating contracting commercial infrastructure and reduced promotional headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HEXA-GERM roles are limited and defensive in nature, focused on maintaining market share and managing decline rather than innovation or expansion. Career progression on this product is constrained by its LOE-approaching status and lack of linked job opportunities (0 positions currently available).
Brand ManagerProduct Manager
Worked on HEXA-GERM at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.